Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 82

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Non-small cell lung cancer

Not recruiting

Study Comparing Dostarlimab and Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Glaxosmithkline Research & Development Limited

K-ras gene mutation+2

Not recruiting

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Vestre Viken HF

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemotherapy and Radiation Therapy

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Pneumonia+1

Not recruiting

Study on Glutathione and Sodium Chloride for Preventing Heart Injury in Pneumonia Patients

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glutathione
  • Sponsor:Biomedica Foscama Industria Chimico-Farmaceutica S.p.A.

Hepatic cancer+1

Not recruiting

Study on Atezolizumab for Patients with Lung and Liver Cancer Using Digital Health Solutions

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Not recruiting

Study of Amivantamab with Carboplatin and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer stage IV+2

Not recruiting

Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brigatinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Gastric cancer+7

Not recruiting

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with EGFR Mutation-Positive Stage II-IIIB Non-Small Cell Lung Cancer After Tumor Removal

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer stage IV

Not recruiting

Study Comparing Nivolumab and Ipilimumab with Chemotherapy to Chemotherapy Alone for Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Non-small cell lung cancer

Not recruiting

Study of Tobemstomig with Platinum-Based Chemotherapy vs Pembrolizumab with Platinum-Based Chemotherapy for Untreated Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.